Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antisense oligonucleotide MDM2 - Idera Pharmaceuticals

Drug Profile

Research programme: antisense oligonucleotide MDM2 - Idera Pharmaceuticals

Alternative Names: GEM 240; HDMAS5; Research programme: anti-MDM2 antisense oligonucleotides

Latest Information Update: 20 Dec 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Idera Pharmaceuticals; Johns Hopkins University; University of Alabama
  • Developer Genzyme Corporation; Idera Pharmaceuticals; University of Alabama
  • Class Antineoplastics; Nucleotides
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 31 Mar 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 13 Sep 2005 Hybridon is now called Idera Pharmaceuticals
  • 05 Mar 2004 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top